Association of P53 Nuclear Overexpression and Tumor Progression in Carcinoma in situ of the Bladder-Reference-Cited by-同舟云学术

Association of P53 Nuclear Overexpression and Tumor Progression in Carcinoma in situ of the Bladder

Published:1994-08 Issue:2 Part 1 Volume:152 Page:388-392
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Sarkis Alvaro S.¹,Dalbagni Guido¹,Cordon-Cardo Carlos¹,Melamed Jonathan¹,Zhang Zuo-Feng¹,Sheinfeld Joel¹,Fair William R.¹,Herr Harry W.¹,Reuter Victor E.¹

Affiliation:

1. From the Urology Service, and Departments of Pathology, and Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference38 articles.

1. Carcinoma in situ of the bladder;Herr;Sem. Urol.,1983

2. Carcinoma in situ of the bladder;Utz;Cancer,1980

3. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms;Prout;Cancer,1983

4. Mapping of the urinary bladder: its impact on the concepts of bladder cancer;Koss;Hum. Path.,1979

5. Intravesical Evans bacille Calmette-Guerin in the treatment of carcinoma in situ;Cumming;Brit. J. Urol.,1989

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pioglitazone, Bladder Cancer, and the Presumption of Innocence;Current Drug Safety;2022-11

2. p53 null phenotype is a “positive result” in urothelial carcinoma in situ;Modern Pathology;2022-09

3. Non-muscle invasive bladder cancer biomarkers beyond morphology;Frontiers in Oncology;2022-08-03

4. Urinary Bladder and Urachus;Handbook of Practical Immunohistochemistry;2022

5. Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer;Minerva Urologica e Nefrologica;2020-06